Abramson Cancer Center at Penn Medicine
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Eligibility Criteria Arm A: * Age 60 years or older. * New diagnosis of Acute Leukemia or MDS, or suspected diagnosis. * Able to consent to the study. Eligibility Criteria Arm B: * Age 60 years or older with a hematologic malignancy. * Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy. * Able to consent to the study.
Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.
Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.